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SUMMARY
Objective: To improve the accuracy predictive models of response to neoadjuvant che-
motherapy in breast cancer, cDNA microarray technology was used to study tumor tran-
scriptional profile. Gene signatures associated with predicting the response to neoadju-
vant chemotherapy are the subject of this review. Methods: The data base http://www.
ncbi.nlm.nih.gov/pubmed/ search was conducted by using the words “breast cancer” 
AND “neoadjuvant/primary chemotherapy” AND “gene expression profile/microarray”. 
After excluding the repeats and selecting the publications considered most relevant by 
the authors to be presented, 279 publications were retrieved. Results: The number of 
publications regarding this subject has been increasing over the years, reaching over 50 
in 2010, including the response to different chemotherapeutic drugs, such as anthracy-
clines and taxanes either alone or in combination. The first studies are from early last de-
cade and used microarray platforms produced by the investigators. Recent studies have 
used commercial microarray platforms whose data have been stored in public databases, 
allowing for the analysis of a higher number of samples. Several transcriptional profiles 
associated with the complete pathological response were identified. Other authors used 
the clinical response to treatment as an endpoint, and, in this case, a predictive panel 
of resistance to the chemotherapeutic regimen at issue was determined. This is also a 
key issue, as it can contribute to individualize treatment, allowing patients resistant to 
a certain chemotherapeutic agent to be offered another therapeutic regimen. Conclu-
sion: Identifying patients responsive to chemotherapy is of essential interest and despite 
major steps have been taken, the issue warrants further studies in view of its complexity.
Keywords: Breast neoplasms; neoadjuvant therapy; drug therapy; prognosis; molecular 
biology.
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INTRODUCTION
Adjuvant chemotherapy reduces the mortality from breast 
cancer, being indicated according to the patient and tumor 
characteristics. This includes age, menopause status, 
tumor size, node involvement, differentiation grade, estro-
gen and HER2/neu receptor expression. A challenge to be 
equated is that survival advantage associated with adjuvant 
chemotherapy is described in a group of patients, being 
evaluated in each individual particularly just as a prob-
ability. Thus, we should consider an individual patient risk 
for unnecessary toxicity, since she would be cured after the 
surgical procedure alone or, on the other hand, she would 
not benefit from chemotherapy, having a relapse even if it is 
used. Another issue is whether there are advantages in using 
certain classes of chemotherapeutic agents, such as taxanes 
and anthracyclines in each patient. Therefore, it is highly 
desirable to identify highly accurate predictive markers of 
chemotherapy benefit.
Thus, neoadjuvant chemotherapy is an excellent op-
portunity to study biomarkers, as pathological complete 
response (pCR) is an intermediate endpoint having high 
correlation with a long survival and, therefore, a good prog-
nosis1-3. This makes translational study conduction easier, as 
patients do not need to be followed by long periods. Neoad-
juvant chemotherapy is an option for unresectable locally 
advanced disease, breast inammatory carcinoma and also 
an initial stage disease. In patients with a resectable disease, 
T1-T3 and N0-2, neoadjuvant chemotherapy regimens 
including four anthracycline cycles have been associated 
with a high objective clinical response rate (complete and 
partial response), ranging between 49% and 85%, but a low 
pathological complete response rate (4%-13%) and low dis-
ease progression rate (1%-3% of patients)1-3. The sequential 
use of anthracyclines and taxanes (paclitaxel or docetaxel) 
rises the objective response rate, as well as the pathological 
complete response rate, with the latter reaching 26%-34%, 
associating with the lowest percentage of patients with a 
node involvement compared with an anthracycline-based 
regimen2,4,5. Also the concomitant administration of either 
anthracycline and taxane (doxorubicin and paclitaxel) or 
taxane and non-anthracyclic agent (paclitaxel and cispla-
tin) induces high objective clinical response rate (89%-91%) 
and pathological complete response rate in 14% and 24% of 
cases, respectively6,7.
Isolated tumor markers non-predictive of a pathological 
complete response are rare. Among them, we can mention 
the HER2 tumor expression in the case of trastuzumab ther-
apy. In tumors with HER2/neu overexpression, the combi-
nation of trastuzumab with neoadjuvant chemotherapy is 
observed to translate into a high pathological complete re-
sponse rate, i.e., 65%8. Further markers are associated with 
the pathological complete response (pCR) rate, such as no 
ER expression, anaplastic histology, high proliferation index 
and reduced tumor size5. The pCR to neoadjuvant therapy 
with doxorubicin and cyclophosphamide (AC) was found 
to be correlated to the specific subtype of breast cancer and 
occurs more frequently in HER2(+)- (36%) and basal-like 
(27%) tumors, in contrast with a luminal B (15%) and an 
luminal A (0%). The objective clinical response (complete 
response and partial response) rate is also variable accord-
ing to the subtypes and in ER(+)-tumors (estrogen receptor-
positive) ranges from 39% (luminal A) to 58% (luminal B) 
and, in ER(-) tumors, from 70% (HER2-positive) to 85% 
(basal-like)9.
In the attempt to improve response predictive model ac-
curacy to neoadjuvant chemotherapy, analyses using cDNA 
microarray technology were conducted. The prospect is 
this methodology, which allows a concomitant analysis of 
the tumor overall gene expression, in contrast with stan-
dard immunohistochemical tests, in which the expression 
of only a number of proteins could be analyzed, gives rise 
to advances in the identification of patients responsive to 
chemotherapy. The evaluation of gene signatures associated 
with prediction of response to neoadjuvant chemotherapy 
is this review target.
METHODS
A search in the database http://www.ncbi.nlm.nih.gov/pubmed/ 
was performed by using the keywords: 1) “breast cancer” 
AND “neoadjuvant chemotherapy” AND “gene expression 
profile”; 2) “breast cancer” AND “neoadjuvant chemother-
apy” AND “microarray”; 3) “breast cancer” AND “primary 
chemotherapy” AND “microarray”; 4) “breast cancer” AND 
“primary chemotherapy” AND “gene expression profile”. A 
total of 279 publications were retrieved in this search, ex-
cluded the repeats, with those considered more relevant by 
the authors being chosen for exposition. Interestingly, sev-
eral publications concerning chemotherapy other than neo-
adjuvant chemotherapy were retrieved, but they were not 
considered in this report.
RESULTS
The number of publications on the considered subject has 
been increasing over the years (Figure 1), reaching over 
50 in 2010. The first studies are from early last decade and 
attempted to identify transcriptional patterns which were 
predictive of response to isolated drugs (anthracycline or 
taxane) or in combinations [AC; 5-uorouracil, epirubicin 
and cyclophosphamide, FEC; paclitaxel + FAC (5-uoro-
uracil, doxorubicin and cyclophosphamide); gemcitabine, 
epirubicin an docetaxel] (Table 1). Tumor samples ob-
tained before the beginning of chemotherapy were used to 
analyze the gene expression by using customized microar-
ray platforms, i.e., samples produced by the investigators. 
In these studies, samples were analyzed in a training group 
and they were used to identify a gene expression pattern. 
Next, this transcriptional pattern was tested in a second 
group named validation group, with the model accuracy 
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Table 1 – Transcriptional patterns studies as predictive of response to neoadjuvant chemotherapy
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Figure 1 – Number of yearly publications related to breast 
cancer, gene expression profile (microarray) and primary/
neoadjuvant chemotherapy (PubMed database).
Year
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
in predicting the response being evaluated. In this setting, 
we can mention pioneering studies by Sotiriou10, Chang11, 
Zembutsu12, Ayers13, Hess14, Thuerigen15, including 10-81 
patients in training groups and 6-51 patients in validation 
groups, and they identified different transcriptional profiles 
associated with the response with a 78%-88% accuracy.
In the Brazilian population, our group tried to identify 
gene expression patterns allowing the tumors to be classi-
fied according to their aggressiveness16 and their response 
to neoadjuvant chemotherapy17. In this recent study, 44 
patients with a disease in clinical stage II/III receiving 4 
AC cycles were included. The clinical response determina-
tion followed RECIST criteria18 and 35 patients were clas-
sified as responsive and nine (7 in training group and 2 in 
validation group) as nonresponsive. Ten transcript triplets 
separating the samples with high accuracy were identified. 
Among them, PRSS11 (serine protease 11 or ligand pro-
tein protease 5 of the insulin-like growth factor), MTSS1 
(metastasis suppressor 1) and CLPTM1 (cleft lip and 
palate-associated transmembrane protein), whose expres-
sion sorted correctly all samples out in the training group. 
As an extended study, we tried to determine whether this 
gene triplet expression could be assessed by quantitative 
RT-PCR, a method much more available, maintaining the 
treatment response predictive power. The expression of 
nine genes included in five response rater gene triplets was 
Author/Year n (training/validation) Regimen Gene signature Accuracy
Sotiriou 200210 10 Anthracycline 37G –
Chang 200311 24/6 Docetaxel 92G 88%
Ayers 200413 24/18 T + 4 FAC 74G 78%
Bertucci 200420 26 Doxorubicin – –
Hannemann 200521 31 AC or AD – –
Hess 200614 82/51 T/FAC 30G 95%
Thuerigen 200615 5248 GE or Docetaxel 512G 88%
Folgueira 200616 31/13 4 ac Triplets 84.6%
Bonnefoi 200722 125 FEC or TET – 79-80%
Straver 200929 167 – MammaPrint –
Farmer 200928 63/51 FEC Stromal metagene AUC 0.7
Zembutsu 200912 20 Docetaxel 9G –
Williams 200934 275 FAC
GEM (gene expression 
model)
S 71%, Sp 53%, PPV 
32%, NPV 85%
Tabchy 201035 138 (T/FAC) T/FAC DLDA 30 (30 genes) PPV 38%, NPV 88%
Korde 201036 21 TX 39 categories –
Ronde 201030 191 AC/TX or Trastuzumab + T Melecular subtyping –
Lin 201037 37/13 ET/Zoledronic Acid 23G 92%
Lee 201038 100 T/FAC
Nomogram/DLDA30/in vitro 
COXEN/in vivo COXEN
Nomogram//DLDA30 
AUC 0.73
Rodriguez 201026 105/28 FEC or AC or TET 69G AUC 0.79 (AC)
Bauer 201039 14 TE T/radiotherapy IG (MAP2) –
Bianchini 201025 233 T/FAC
High MKS (mitosis – 
associated kinase score)
RR 2.6 (associated with 
pCR)
Barros Filho 201019 14 4AC Triplets 71%
Chen 201140 55/55 T Cb 20G 80%
Naoi 201141 50/34 T-FEC 106G VPN > 90%
Fan 201142 150/75 T/FAC AUC ~ 0.8
G, genes; N, number of patients; F, 5-fluorouracil; A, doxorubicin; C, cyclophosphamide; T, paclitaxel; G, gemcitabine; E, epirubicin; Cb: carboplatin; X, capecitabina; 
RR, relative risk, AUC, area under curve; pCR, pathological complete response; NPV, negative predictive value; PPV, positive predictive value; S, sensitivity; 
Sp, specificity.
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analyzed in another sample group with 14 patients treated 
with neoadjuvant therapy based on AC. The expression of 
two out of five triplets attributed a correct classification in 
71% of samples in the biological validation group19 (Table 
1), indicating these transcripts are associated with a re-
sponse to chemotherapy. 
A number of other authors included patients with 
specific characteristics; Bertucci et al.20 determined a 
transcriptional pattern associated with pathological com-
plete response to doxorubicin in patients with inamma-
tory carcinoma. CDKN1B (p27), a cell cycle progression 
inhibitor, was observed to have a greater expression in 
tumors with pathological complete response, as well as 
genes encoding chemokines, cytokines, and cytokine re-
ceptors, such as CSF1R, CCL2, CCL3, MMP9, suggesting 
a host immune system role in eradicating tumor follow-
ing chemotherapy20.
In prior cases, we were concerned to identify a predic-
tive signature of response a specific chemotherapy regi-
men. Another investigation approach evaluated whether 
response profiles would be specific or shared by different 
chemotherapy regimens. With this purpose, Hannemann 
et al.21 tried to classify the gene profile in 31 tumor sam-
ples from AC- or AD- (doxorubicin and docetaxel) treat-
ed patients; however, they were not successful. Following 
this hypothesis, but then in a specific tumor subgroup, 
i.e., ER-negative (which are believed to have a higher 
pCR than ER-positive tumors), Bonnefoi et al.22 tried to 
set a neoadjuvant chemotherapy pCR-predictive gene 
signature consisting of 6 FEC or TET (e docetaxel cycles 
followed by 3 epirubicin + docetaxel cycles). One hun-
dred and twenty-five Affymetrix X3P microarray hybrid-
ized samples were studied. The analysis was based on the 
combination of an in vitro cell culture sensitivity profile 
to a specific drug; this data was previously reported23. The 
predictive signature showed an accuracy to predict re-
sponse of 79% and 80% in FEC and TET groups, respec-
tively. However, a similar study conducted by another 
group, considering the same hypothesis and using a gene 
panel identified by its correlation with breast cancer lin-
eage sensitivity to four chemotherapeutic agents alone, 
did not reproduce the response prediction outcomes in 
patients treated with a combination of these drugs (pacli-
taxel followed by FAC)24.
More recent studies, published in 2009-2011, use 
commercial microarray platforms, such as Mammaprint, 
Affymetrix HG-U133A, for gene expression analysis. 
From results obtained more homogenously and stored in 
public data bases, studies with bioinformatic analysis of a 
higher number of samples present in the data bases were 
generated. Generally, pathways that might be involved 
in mechanisms associated with proliferation process, 
DNA repair, chemotherapy resistance, and others are ad-
dressed.
In one of these studies, Bianchini et al.25 evaluated the 
profile of mitosis-associated kinase expression and ob-
served that a high score was associated with a higher pCR 
probability, but also with a poorer prognosis, in ER-posi-
tive tumors. Interestingly, this profile, contrary to expecta-
tions, is not related to a pathological complete response 
and a good prognosis.
Drawing on this in silico database analysis strategy, Ro-
driguez et al.26 analyzed the profile of triple negative tu-
mors regarding the expression profile of BRCA1 mutation-
associated DNA repair genes. In this case, patients treated 
with several chemotherapy regimens (FEC, AC, TET) were 
included, and an expression defective pattern of this repair 
gene panel was associated with a response to doxorubicin 
and resistance to taxanes. Staying on in silico analysis and 
using gene set coordinate expression analysis, Iwamoto et 
al.27 suggest the profile associated with cell proliferation is 
correlated to chemotherapy response in ER-positive tu-
mors, but not in ER-negative tumors. In addition, Farmer 
et al.28 found stroma gene expression is associated with 
ER-negative tumor resistance to neoadjuvant treatment 
with two regimens containing different anthracyclines, 
FEC and T-FAC. Interestingly, this stroma signature did 
not predict relapse-free survival in patients who did not 
undergo chemotherapy, indicating this is not a prognostic 
factor, but a treatment response predictive factor28.
Another experimentation attack involved the analysis 
of profiles already established for their relation to disease 
prognosis. Studies such as that by Straver et al.29 tested 
the hypothesis that the prognostic signature of 70 Mam-
maprint genes would also be predictive of a response to 
chemotherapy. For this purpose, 166 neoadjuvant che-
motherapy-treated patients (various regimens) were in-
cluded, with 86% and 14% being classified as having poor 
and good prognosis, respectively. No patients with a good 
prognosis signature (0/23) had a pCR, in contrast with 
29/144 patients with a poor prognosis. Thus, Mammap-
rint signature seems to be predictive of a chemotherapy 
benefit29.
Otherwise, Ronde et al.30 analyzed whether transcrip-
tional profile could additionally contribute to chemo-
therapy response prediction in histological subtypes de-
fined by immunohistochemistry (triple negative tumors; 
HER2-positive; luminal [ER-positive/HER2-negative] 
tumors). In this study, 195 tumors were compared regard-
ing subtypes defined by immunohistochemistry and by 
mRNA expression profile (basal, HER2-positive, luminal 
A, Luminal B and normal-like) and tested for the power to 
predict a neoadjuvant chemotherapy complete response. 
The results found HER2-positive tumors, according to the 
immunohistochemical test, could not be classified as such 
by the molecular profile and, when this occurs, the che-
motherapy response rate is low (8%) versus 54% in HER2-
positive tumors, according to the gene profile analysis.
TRANSCRIPTIONAL PROFILE AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER
351Rev Assoc Med Bras 2011; 57(3):347-352
DISCUSSION
We observed the subject “Transcriptional profile and response 
to neoadjuvant chemotherapy in breast cancer” is a reason for 
increasingly concern, in view of the number of studies being 
produced; however, numerous questions remain.
A number of neoadjuvant chemotherapy response-
predictive gene expression profiles were identified, prob-
ably contributing to a better understanding of mechanisms 
involved in treatment resistance. However, these transcrip-
tional profiles are heterogeneous and probably reect the 
chemotherapy response biological complexity. The question 
is whether the different panels are superimposable and iden-
tify the same tumor regarding treatment response and there 
are more homogenous patterns at other transcriptional and 
translational regulation levels. Worth remembering tumor 
gene signature is strongly linked to disease prognosis31,32 
and most neoadjuvant chemotherapy response-predictive 
gene expression profiles ever described are based on the 
pathological complete response, thus, they are partly linked 
to prognosis. Nevertheless, recent studies indicate pCR-pre-
dictive transcriptional signature might not be related to a 
disease good prognosis25,28,29.
On the other hand, a number of authors use the treat-
ment clinical response as an endpoint11,17,28. As in this case 
objective response is considered versus no response (stable 
disease and disease progression), a resistance predictive 
panel to a chemotherapeutic regimen concerned is deter-
mined. This issue is also essential, as it can contribute to 
individualize the treatment regimen, allowing patients re-
sistant to a determined chemotherapeutic agent undergo 
another therapeutic regimen.
Chemotherapeutic resistance seems complex. A number 
of resistance mechanisms may be common to several drugs, 
such as MDR1 e MRP gene expression, encoding a membrane 
glycoprotein causing drug extrusion. Another example are 
the apoptosis machinery changes by BCL2 overexpression, 
BAX lower expression, TP53 mutation, H-RAS oncogene ex-
pression, MDM2 expression. Moreover, the medication itself, 
by interacting with DNA, can cause additional mutations. 
In order to study intrinsic and acquired tumor resistance in 
breast cancer, we used the strategy of assessing the differential 
gene expression between treatment resistant patient samples 
(stable disease and disease progression) and residual samples 
considered early responders (partial response). In this case, 
we observed regulated pathways are JNK and apoptosis, 
which can contribute to the resistance process, and that a 
higher CTGF and DSUP1 expression in residual samples may 
reect the resistance to additional AC cycles33.
CONCLUSION
In short, the identification of chemotherapy responsive pa-
tients is of central interest and despite important steps have 
been taken, the subject deserves additional studies in view 
of its complexity.
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